Olanzapine-Risperidone LA

From Psychiatrienet
Jump to: navigation, search
Olanzapine
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AH03
Medscape Olanzapine
EMEA zyprexa
PubChem 4585
PubMed Olanzapine
Drugs.com olanzapine
Kompas (Dutch) Olanzapine
Wikipedia Olanzapine
Risperidone
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone

Switch medication from Olanzapine to Risperidone_LA.

Nietinrijdenbord.png Stop Olanzapine
  • Day 1-14: Continue drug at usual dose
  • Day 15-18: approx. 75% of initial dose
  • Day 19-22: approx. 50% of initial dose
  • Day 23-27: approx. 25% of initial dose
  • Day 28: stop
Eenrichtingbord.png Start Risperidone_LA
  • Day 1: Start depot according general dosing advice (Dotted line in graph)
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[4]
  • Alternatively, first switch to oral form and then switch to depot to manage possible (adverse) reactions. With a direct switch to a depot it is advisable to administer a low testdose in order to exclude adverse reactions.
    Stop28DaysStartDepotRisp.jpg
Nietinrijdenbord.png — Olanzapine
Eenrichtingbord.png — Risperidone_LA


  1. 1.0 1.1 1.2 1.3 KNMP; Informatorium Medicamentorum 2015; Monografie "olanzapine" (Dutch)
  2. Farmacotherapeutisch Kompas; Toxicologie (dutch)
  3. Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003;64:663-667
  4. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.